About Fennec Pharmaceuticals Inc.
https://www.fennecpharma.comFennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.
CEO
Jeffrey S. Hackman
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2014-09-09 | Reverse | 1:3 |
| 2011-08-31 | Reverse | 1:18 |
ETFs Holding This Stock
Summary
Showing Top 3 of 33
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
SOUTHPOINT CAPITAL ADVISORS LP
Shares:4.08M
Value:$30.91M
SONIC GP LLC
Shares:2.41M
Value:$18.25M
SONIC FUND II, L.P.
Shares:2.41M
Value:$18.25M
Summary
Showing Top 3 of 95
About Fennec Pharmaceuticals Inc.
https://www.fennecpharma.comFennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $12.46M ▲ | $11.99M ▲ | $-638K ▲ | -5.12% ▲ | $-0.02 ▲ | $-1K ▲ |
| Q2-2025 | $9.65M ▲ | $11.42M ▲ | $-3.15M ▼ | -32.66% ▼ | $-0.12 ▼ | $-2.53M ▼ |
| Q1-2025 | $8.75M ▲ | $9.19M ▲ | $-1.17M ▲ | -13.31% ▲ | $-0.04 ▲ | $-782K ▲ |
| Q4-2024 | $7.92M ▲ | $8.19M ▼ | $-1.99M ▲ | -25.05% ▲ | $-0.07 ▲ | $-909K ▲ |
| Q3-2024 | $6.97M | $10.82M | $-5.74M | -82.23% | $-0.21 | $-4.68M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $21.93M ▲ | $49.21M ▲ | $53.7M ▲ | $-4.49M ▲ |
| Q2-2025 | $18.7M ▼ | $44.88M ▼ | $52.34M ▲ | $-7.46M ▼ |
| Q1-2025 | $22.68M ▼ | $46.4M ▲ | $52.28M ▲ | $-5.88M ▼ |
| Q4-2024 | $26.63M ▼ | $44.95M ▼ | $50.82M ▼ | $-5.87M ▼ |
| Q3-2024 | $40.32M | $58.92M | $64.09M | $-5.17M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-637K ▲ | $1.49M ▲ | $0 | $1.75M ▲ | $3.24M ▲ | $1.49M ▲ |
| Q2-2025 | $-3.15M ▼ | $-3.69M ▲ | $0 | $-284K ▼ | $-3.97M ▼ | $-3.69M ▲ |
| Q1-2025 | $-1.17M ▲ | $-4.32M ▼ | $0 | $359K ▲ | $-3.96M ▲ | $-4.32M ▼ |
| Q4-2024 | $-1.99M ▲ | $-1.47M ▲ | $0 | $-12.21M ▼ | $-13.69M ▼ | $-1.47M ▲ |
| Q3-2024 | $-5.74M | $-2.21M | $0 | $-528K | $-2.73M | $-2.21M |
CEO
Jeffrey S. Hackman
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2014-09-09 | Reverse | 1:3 |
| 2011-08-31 | Reverse | 1:18 |
ETFs Holding This Stock
Summary
Showing Top 3 of 33
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
SOUTHPOINT CAPITAL ADVISORS LP
Shares:4.08M
Value:$30.91M
SONIC GP LLC
Shares:2.41M
Value:$18.25M
SONIC FUND II, L.P.
Shares:2.41M
Value:$18.25M
Summary
Showing Top 3 of 95